APA (7th ed.) Citation

Dickson, S. P., Mallinckrodt, C., Burstein, A. H., Nisenbaum, L., Fillit, H. M., & Hendrix, S. B. (2024). The impact of lecanemab and donanemab on future Alzheimer's disease clinical development. Alzheimer's & dementia: the journal of the Alzheimer's Association, 20(S6), 1. https://doi.org/10.1002/alz.093476

Chicago Style (17th ed.) Citation

Dickson, Samuel P., Craig Mallinckrodt, Aaron H. Burstein, Laura Nisenbaum, Howard M. Fillit, and Suzanne B. Hendrix. "The Impact of Lecanemab and Donanemab on Future Alzheimer's Disease Clinical Development." Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20, no. S6 (2024): 1. https://doi.org/10.1002/alz.093476.

MLA (9th ed.) Citation

Dickson, Samuel P., et al. "The Impact of Lecanemab and Donanemab on Future Alzheimer's Disease Clinical Development." Alzheimer's & Dementia: The Journal of the Alzheimer's Association, vol. 20, no. S6, 2024, p. 1, https://doi.org/10.1002/alz.093476.